Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Checkpoint inhibitors provided sustained clinical benefit to metastatic lung cancer patients. Nonetheless, prognostic markers in metastatic settings are still under research. Imaging offers distinctive advantages, providing whole-body information non-invasively, while routinely available in most clinics. We hypothesized that more prognostic information can be extracted by employing artificial intelligence (AI) for treatment monitoring, superior to 2D tumor growth criteria. Methods: A cohort of 152 stage-IV non-small-cell lung cancer patients (NSCLC) (73 discovery, 79 test, 903CTs), who received nivolumab were retrospectively collected. We trained a neural network to identify morphological changes on chest CT acquired during patients’ follow-ups. A classifier was employed to link imaging features learned by the network with overall survival. Results: Our results showed significant performance in the independent test set to predict 1-year overall survival from the date of image acquisition, with an average area under the curve (AUC) of 0.69 (p < 0.01), up to AUC 0.75 (p < 0.01) in the first 3 to 5 months of treatment, and 0.67 AUC (p = 0.01) for durable clinical benefit (6 months progression-free survival). We found the AI-derived survival score to be independent of clinical, radiological, PDL1, and histopathological factors. Visual analysis of AI-generated prognostic heatmaps revealed relative prognostic importance of morphological nodal changes in the mediastinum, supraclavicular, and hilar regions, lung and bone metastases, as well as pleural effusions, atelectasis, and consolidations. Conclusions: Our results demonstrate that deep learning can quantify tumor- and non–tumor-related morphological changes important for prognostication on serial imaging. Further investigation should focus on the implementation of this technique beyond thoracic imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository
Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M., et al. (2013) · Journal of Digital Imaging · doi:10.1007/s10278-013-9622-7 · Cited by 4,599
Armato, S. G., McLennan, G., Bidaut, L., McNitt‐Gray, M. F., Meyer, C. R., Reeves, A. P., Zhao, B., Aberle, D. R., Henschke, C. I., Hoffman, E. A., et al. (2011) · Medical Physics · doi:10.1118/1.3528204 · Cited by 2,887
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 1×
“This is particularly relevant in patients treated with anti PD-1 blockade where lymphadenopathy (14, 15), parenchymal in fl ammations, edema (16, 17), and compression atelectasis (18), can be observed.”
BackgroundThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
RECIST 1.1—Update and clarification: From the RECIST committee
Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.081 · Cited by 1,906
Artificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Self-citationSun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236
Deep learning in medical image registration: a survey
Haskins, G., Kruger, U., & Yan, P. (2020) · Machine Vision and Applications · doi:10.1007/s00138-020-01060-x · Cited by 704 · cited 1×
“While conventional registration techniques are very limited for this application, deep learning-based methods have shown promise in image-to-image registration (20).”
BackgroundYan, K., Wang, X., Lu, L., & Summers, R. M. (2018) · Journal of medical imaging · doi:10.1117/1.jmi.5.3.036501 · Cited by 573 · cited 1×
“Research efforts, however, have to be made in order to overcome the bottleneck of manual ROI delineation procedures, either in the form of automatic segmenters (33), or with implicit AI representations of the total tumor burden.”
BackgroundWang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471 · cited 1×
“In the context of oncological research, most predictive/prognostic markers are derived from tissue samples, routinely-extracted blood (9), or non-invasive radiological imaging (surrogate imaging markers).”
BackgroundDevelopment of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer
Tang, C., Hobbs, B., Amer, A., Li, X., Behrens, C., Canales, J. R., Cuentas, E. P., Villalobos, P., Fried, D., Chang, J. Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20471-5 · Cited by 154
Cited by
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Artificial Intelligence in Pharmaceutical and Healthcare Research
Bhattamisra, S. K., Banerjee, P., Gupta, P., Mayuren, J., Patra, S., & Candasamy, M. (2023) · Big Data and Cognitive Computing · doi:10.3390/bdcc7010010 · Cited by 257
She, Y., He, B., Wang, F., Zhong, Y., Wang, T., Liu, Z., Yang, M., Yu, B., Deng, J., Sun, X., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104364 · Cited by 91
Li, D., Pehrson, L. M., Lauridsen, C. A., Tøttrup, L., Fraccaro, M., Elliott, D., Zając, H. D., Darkner, S., Carlsen, J. F., & Nielsen, M. B. (2021) · Diagnostics · doi:10.3390/diagnostics11122206 · Cited by 35
Advances in artificial intelligence applications in the field of lung cancer
Yang, D., Miao, Y., Liu, C., Zhang, N., Zhang, D., Guo, Q., Gao, S., Li, L., Wang, J., Liang, S., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1449068 · Cited by 18
Metadata
- Authors
- Trebeschi, S., Bodalal, Z., Boellaard, T. N., Tareco Bucho, T. M., Drago, S. G., Kurilova, I., Calin-Vainak, A. M., Delli Pizzi, A., Muller, M., Hummelink, K., Hartemink, K. J., Nguyen-Kim, T. D. L., Smit, E. F., Aerts, H. J. W. L., & Beets-Tan, R. G. H.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-02
- Volume
- 11
- Pages
- 609054-609054
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3135381278
- Cited by
- 54
- References
- 11
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.